ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.55
0.18%
US Tech 100
18,752.80
-0.79%
S&P 500
5,499.40
-0.47%
US Dollar vs CAD
1.38503
-0.16%
Bitcoin
93,915.45
0.17%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Bristol Myers Squibb Co (BMY) Share Price

Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY)

Bloomsbury Publishing Plc
48.145
0.245
( 0.51% )
Updated: 13:19:12
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
48.145
Bid
-
Ask
-
Volume
8,046,196
47.92 Day's Range 48.86
39.35 52 Week Range 63.33
Market Cap
97.701B
Previous Close
47.90
Open
48.31
Last Trade
27
@
48.145
Last Trade Time
13:19:16
Financial Volume
US$ 388,731,410
VWAP
48.3124
Average Volume (3m)
13,608,832
Shares Outstanding
2,029,312,023
Dividend Yield
5.15%
PE Ratio
-10.88
Earnings Per Share (EPS)
-4.41
Revenue
48.3B
Net Profit
-8.95B

About Bristol Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.bms.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Bristol Myers Squibb Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker BMY. The last closing price for Bristol Myers Squibb was US$47.90. Over the last year, Bristol Myers Squibb shares have traded in a share price range of US$ 39.35 to US$ 63.33.

Bristol Myers Squibb currently has 2,029,312,023 shares outstanding. The market capitalization of Bristol Myers Squibb is US$97.20 billion. Bristol Myers Squibb has a price to earnings ratio (PE ratio) of -10.88.

Ask ADVFN Intelligence (AI)

Bristol Myers Squibb (BMY) Options Flow Summary

BMY Options Flow

Overall Flow

Bearish

Net Premium

-12M

Calls / Puts

38.89%

Buys / Sells

120.00%

OTM / ITM

25.00%

Sweeps Ratio

0.00%

BMY Latest News

More News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
April 25 2025
BMY (0.51%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
April 24 2025
BMY (0.51%)

Form 8-K - Current report
Edgar (US Regulatory)
April 24 2025
BMY (0.51%)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Edgar (US Regulatory)
April 17 2025
BMY (0.51%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.145-2.3229864069849.2950.05546.931688945848.70170872CS
4-11.655-19.489966555259.861.6446.931555858752.08879278CS
12-10.455-17.841296928358.663.3346.931360883256.30853329CS
26-3.715-7.1635171615951.8663.3346.931207579256.71622638CS
522.9556.5390573135645.1963.3339.351281015050.81462917CS
156-28.625-37.286700534176.7781.43539.351185862958.68491255CS
260-14.785-23.494358811462.9381.43539.351188822260.46222549CS

BMY - Frequently Asked Questions (FAQ)

What is the current Bristol Myers Squibb share price?
The current share price of Bristol Myers Squibb is US$ 48.145
How many Bristol Myers Squibb shares are in issue?
Bristol Myers Squibb has 2,029,312,023 shares in issue
What is the market cap of Bristol Myers Squibb?
The market capitalisation of Bristol Myers Squibb is USD 97.2B
What is the 1 year trading range for Bristol Myers Squibb share price?
Bristol Myers Squibb has traded in the range of US$ 39.35 to US$ 63.33 during the past year
What is the PE ratio of Bristol Myers Squibb?
The price to earnings ratio of Bristol Myers Squibb is -10.88
What is the cash to sales ratio of Bristol Myers Squibb?
The cash to sales ratio of Bristol Myers Squibb is 2.02
What is the reporting currency for Bristol Myers Squibb?
Bristol Myers Squibb reports financial results in USD
What is the latest annual turnover for Bristol Myers Squibb?
The latest annual turnover of Bristol Myers Squibb is USD 48.3B
What is the latest annual profit for Bristol Myers Squibb?
The latest annual profit of Bristol Myers Squibb is USD -8.95B
What is the registered address of Bristol Myers Squibb?
The registered address for Bristol Myers Squibb is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Bristol Myers Squibb website address?
The website address for Bristol Myers Squibb is www.bms.com
Which industry sector does Bristol Myers Squibb operate in?
Bristol Myers Squibb operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WOLFWolfspeed Inc
US$ 4.16
(27.22%)
52.86M
AOMRAngel Oak Mortgage REIT Inc
US$ 9.54
(12.50%)
174.88k
CLBRColombier Acquisition Corp
US$ 12.79
(11.22%)
7.11M
AMPYAmplify Energy Corp
US$ 2.965
(10.22%)
9.09M
ADCTADC Therapeutics SA
US$ 1.4656
(10.20%)
251.5k
FINS.RTAngel Oak Financial Strategies Income Term Trust
US$ 0.021701
(-27.66%)
89.39k
VLRSVolaris Aviation Holding
US$ 4.085
(-12.71%)
3.56M
EAFGrafTech International Ltd
US$ 0.62325
(-11.51%)
1.27M
LVWRLivewire Group Inc
US$ 1.89
(-10.00%)
25.77k
SSTSystem1 Inc
US$ 0.370101
(-9.07%)
71.01k
BBAIBigBear ai Holdings Inc
US$ 3.465
(-1.84%)
81.35M
FFord Motor Company
US$ 10.005
(-0.35%)
55.86M
WOLFWolfspeed Inc
US$ 4.165
(27.37%)
52.86M
AZULAzul SA
US$ 0.76185
(-8.22%)
48.85M
NIONIO Inc
US$ 4.265
(5.83%)
46.47M

BMY Discussion

View Posts
makinezmoney makinezmoney 2 weeks ago
$BMY: If this one has a 20% day like LLY just had

WOW.

I'm gonna start watching 0dte on these on the weeklys for the next 6months
Every week.

You saw what happened to $LLY today................ $BMY can happen too if they come out with a Obesity PILL FDA approved

$BMY $70 4/25 calls are at $0.01 right now............... can they go to $100 for Next FRIDAY ???

GO $BMY
👍️0
Monksdream Monksdream 2 weeks ago
BMY
👍️0
Monksdream Monksdream 6 months ago
BMY, new 52=high
👍️0
TechandBio TechandBio 7 months ago
Schizo drug approval coming?
Deep Pipeline.
$BMY
👍️0
morokoy morokoy 7 months ago
Keeping an eye on this one, looking for a repeat. Bought on 7/9, sold 8/9 for a 15.96% gain.
Record date is 10/4, looking at $50.00 9/27 Options to get me in on time. Divvy is $0.60
Will see what develops.
👍️0
Monksdream Monksdream 7 months ago
BMY range bound
👍️0
Nebuchadnezzar Nebuchadnezzar 9 months ago
easy mOnAAy BMY
👍️0
Nebuchadnezzar Nebuchadnezzar 9 months ago
safest buy in market right now at $39-$42

other safe bets

PFE CSCO SLB BP CAG HRL CPB
👍️0
Sirpeter Sirpeter 9 months ago
Boom
👍️0
Money hunt Money hunt 10 months ago
RNAZ Buyout coming….
👍️0
DewDiligence DewDiligence 2 years ago
AZN pays BMY/Ono Pharma $510M to_settle_all_patent_litigation_regarding Imjudo/Imfinzi:

https://www.fiercepharma.com/pharma/bristol-myers-astrazeneca-settle-pd-1-ctla-4-cancer-immunotherapy-patent-suits-510m
👍️0
DewDiligence DewDiligence 2 years ago
BMY 2Q23 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/07/27/bristol-myers-squibb-bmy-q2-2023-earnings-call-tra
👍️0
DewDiligence DewDiligence 2 years ago
BMY reports 2Q23 results—cuts 2023 non-GAAP EPS guidance:

PR:
https://s21.q4cdn.com/104148044/files/doc_financials/quarterly_reports/2023/BMY-Q22023-Earnings-Press-Release.pdf

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2023/BMY-2023-Q2-Results-Investor-Presentation-Appendix.pdf


2023 non-GAAP EPS guidance is now $7.35-7.65, down $0.60 from the prior range of $7.95-8.25. The new guidance represents a 4% YoY decline at the midpoint of the range. The reason for the cut is lower expected sales of Revlimid (now generic) and Pomalyst (soon to be generic).
👍️0
DewDiligence DewDiligence 2 years ago
Opdivo monotherapy—>statsig OS/PFS as_addend_to_cisplatin_in first-line bladder cancer:

https://finance.yahoo.com/news/opdivo-nivolumab-combination-cisplatin-based-105900450.html

The trial in question is a 600-patient sub-study of CHECKMATE-901, which is now complete. (The other part of CHECKMATE-901, which compares Opdivo/Yervoy vs chemo, is ongoing.) The trial had no requirement for PD-L1 expression.

Today’s PR does not contain a hazard ratio or any other detailed results; those data will be presented at an unspecified medical conference.

Opdivo for bladder cancer is already FDA-approved in the adjuvant (#msg-165546303) and second-line (#msg-128386168) settings. Approval in the first-line (unresectable or metastatic) setting would give Opdivo across-the-board coverage for bladder cancer.
👍️0
DewDiligence DewDiligence 2 years ago
BMY opts-in for worldwide rights_to PRTA’s anti-tau compound, PRX005:

https://www.businesswire.com/news/home/20230710599297/en

PRTA reported phase-1 data for PRX005 in Alzheimer’s disease in Jan 2023 (#msg-171085895).

BMY opted in for the US rights to PRX005 in 2021 (#msg-164573926), which resulted in an $80M milestone payment to PRTA. Today’s opt-in for the ex-US rights generates an additional $55M payment to PRTA.

This collaboration, which BMY inherited from CELG (#msg-139431013), potentially includes two drug candidates in addition to PRX005 (one targeting TDP-43 and one with an undisclosed target), but BMY has as yet opted in only for PRX005 and has shown no interest in the other two candidates, as far as I know.
👍️0
DewDiligence DewDiligence 2 years ago
GERN submits Imetelstat NDA for treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes:

https://www.businesswire.com/news/home/20230620336071/en

This is an indication where BMY is seeking FDA approval for Reblozyl and where Reblozyl is already approved in the EU.
👍️0
DewDiligence DewDiligence 2 years ago
BMY sues US government regarding IRA:

https://www.bms.com/impact-of-the-inflation-reduction-act-on-innovative-medicines-for-patients.html

The arguments are very similar to MRK’s IRA lawsuit (#msg-172068691). It seems pretty likely that these lawsuits will eventually be consolidated.
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s ASCO slide set:

https://s21.q4cdn.com/104148044/files/doc_presentations/2023/bmy-asco-investor-presentation.pdf

These are the slides that accompanied BMY’s investor webcast today.
👍️0
DewDiligence DewDiligence 2 years ago
Opdivo bests Adcetris in first-line-HL PFS—immature_OS_data_trending_in_favor_of_Opdivo:

https://www.fiercepharma.com/pharma/seagens-top-selling-drug-under-threat-bristol-myers-opdivo-beats-adcetris-lymphoma Compared with Adcetris, Bristol Myers Squibb’s Opdivo significantly reduced the risk of cancer progression or death by 52% [i.e. the HR for PFS was 0.48—Dew] in adults and children with newly diagnosed stage 3 or 4 classical Hodgkin lymphoma, according to phase 3 data unveiled at the 2023 American Society of Clinical Oncology annual meeting. Both drugs were used on top of the AVD regimen of chemotherapy.

The collaborative group-conducted trial, coded SWOG S1826, randomized nearly 1,000 patients. The results point to Opdivo-AVD as “a new standard of care that is better tolerated and results in a higher proportion of patients with durable remissions” than Adcetris-AVD, Oreofe Odejide, M.D., from the Dana-Farber Cancer Institute and an invited ASCO expert, said in a statement.

…Opdivo is currently only allowed in HL following Adcetris treatment thanks to an FDA accelerated approval in 2016. The new SWOG trial will support an FDA filing for Opdivo in front-line treatment, Herrera told Fierce Pharma in an interview. It could also help Bristol Myers turn the original conditional nod into a full approval.

…The Opdivo regimen has yet to show a significant patient survival benefit. By the data cutoff, 11 (2.2%) deaths happened in the Adcetris arm, compared with four (0.8%) for Opdivo. It will take a few years for the OS data from this trial to reach maturity.
👍️0
DewDiligence DewDiligence 2 years ago
Repotrectinib NDA has 11/27/23 PDUFA date—(with FDA priority review):

https://finance.yahoo.com/news/u-food-drug-administration-accepts-105900511.html

The indication is locally advanced or metastatic ROS1-positive NSCLC.
👍️0
DewDiligence DewDiligence 2 years ago
CHMP approves Opdivo/chemo in neoadjuvant NSCLC:

https://www.businesswire.com/news/home/20230525005752/en
👍️0
DewDiligence DewDiligence 2 years ago
Milvexian—>FDA Fast Track designation for_all_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three indications BMY is pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF.
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s BMS-986278 for IPF will advance to phase-3:

https://www.businesswire.com/news/home/20230519005266/en
👍️0
DewDiligence DewDiligence 2 years ago
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s ASCO/EHA/ICML lineup:

https://www.businesswire.com/news/home/20230510006079/en
👍️0
DewDiligence DewDiligence 2 years ago
$3.4M insider sale yesterday by BMY’s CSO, Rupert Vessey:

https://www.sec.gov/Archives/edgar/data/14272/000001427223000114/xslF345X04/wf-form4_168323704827586.xml

Unless Vessey is buying a house, a sale of this size at this price level is somewhat concerning.
👍️0
DewDiligence DewDiligence 2 years ago
BMY 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-bristol-myers-squibb-042637576.html
👍️0
DewDiligence DewDiligence 2 years ago
BMY 1Q23 results…

PR:
https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2023/default.aspx

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2023/BMY-2023-Q1-Results-Presentation-Appendix.pdf

2023 non-GAAP EPS guidance remains $7.95-8.25, +4% YoY at the midpoint of the range.
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s CCO, Christopher Boerner—>CEO effective 11/1/23:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000014272/000114036123020605/brhc20052030_8k.htm

CEO, Giovanni Caforio will become Executive Chairman on 11/1/23. Between now and 11/1/23, Boerner will have the title of COO.
👍️0
DewDiligence DewDiligence 2 years ago
CHMP approves Camzyos:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-184200509.html
👍️0
DewDiligence DewDiligence 2 years ago
CHMP approves Breyanzi in second-line LBCL:

https://www.businesswire.com/news/home/20230330005697/en

FDA approval in this indication came in Jun 2022 (#msg-169240243).
👍️0
DewDiligence DewDiligence 2 years ago
BMY, EVO extend/expand neurodegeneration collaboration:

https://www.accesswire.com/viewarticle.aspx?id=746175&lang=en

The collaboration now runs for another eight years, and EVO receives an additional $50M in up-front cash.

Note that BMY and EVO are also collaborating in protein degradation (#msg-168811996).
👍️0
DewDiligence DewDiligence 2 years ago
EC approves Sotyktu for psoriasis:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-105900011.html

Essentially same label as FDA’s.
👍️0
DewDiligence DewDiligence 2 years ago
TAK-279 vs Sotyktu (from biopharmadive.com): #msg-171480207.
👍️0
DewDiligence DewDiligence 2 years ago
BMY will not launch Opdualag in Germany due to pricing constraints on FDC (combination) drugs:

https://endpts.com/bristol-myers-axes-german-launch-of-new-cancer-drug-citing-pricing-hurdles/
👍️0
DewDiligence DewDiligence 2 years ago
BMY/JNJ unveil_phase-3_program_for Milvexian—50,000 patients_across_three_ trials_in secondary stoke prevention, ACS, and AF/primary stroke prevention:

https://www.businesswire.com/news/home/20230228006466/en Enrollment has begun for the Librexia STROKE trial, which is evaluating milvexian in addition to standard of care antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack. The Librexia ACS trial, which will evaluate event reduction in acute coronary syndromes in addition to standard of care antiplatelet therapy, and the Librexia AF trial, which will investigate milvexian compared to apixaban [Eliquis] in the prevention of stroke in patients with atrial fibrillation, will also initiate during the first half of 2023. Milvexian is an oral FXIa inhibitor. The phase-3 trial in secondary stroke prevention is at: https://www.clinicaltrials.gov/ct2/show/NCT05702034 .

The commercial impetus for the Milvexian program is to supersede Eliquis (BMY) and Xarelto (JNJ) when those drugs go off-patent or become subject to Medicare price-setting. The competition for Milvexian is Bayer’s Asundexian, another oral FXIa inhibitor that started a somewhat less aggressive phase-3 program (#msg-169841711) that does not have a trial for ACS.
👍️0
DewDiligence DewDiligence 2 years ago
Opdivo PDUFA date for adjuvant melanoma—>10/13/23:

https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900042.html

The corresponding MAA has been validated by the EMA, starting the review clock.

The sBLA and MAA are based on the CHECKMATE-076 study, which showed HR=0.42 for the primary RFS endpoint (#msg-170239823).
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s ACC lineup:

https://www.businesswire.com/news/home/20230224005299/en
👍️0
DewDiligence DewDiligence 2 years ago
BMY/TVST report Abecma data from phase-3 KarMMa-3 study:

https://www.businesswire.com/news/home/20230209005647/en At a median follow up of 18.6 months, treatment with Abecma (n=254) demonstrated a clinically meaningful and statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared with standard regimens (n=132), with a median PFS of 13.3 months (95% CI: 11.8-16.1) vs. 4.4 months (95% CI: 3.4-5.9), respectively (HR:0.49; p<0.0001).Abecnma is currently FDA-approved for fifth-line MM; the results above should enable a label expansion into the third-line setting.
👍️0
DewDiligence DewDiligence 2 years ago
BMY -2.5% today—possible reason is that the CEO just sold $18M worth of stock—approximately half his holding—(the Form-4 filing hit the wires last night after the close):

https://www.sec.gov/Archives/edgar/data/14272/000001427223000044/xslF345X03/wf-form4_167590496019590.xml

It's hard to interpret a transaction of this size as non-bearish. I wonder if Giovanni Caforio is planning to retire in the next 12-18 months.
👍️0
DewDiligence DewDiligence 2 years ago
Bayer enrolls first phase-3 patients for FXIa inhibitor, Asundexian:

https://www.businesswire.com/news/home/20230208005322/en
• The OCEANIC program will investigate the efficacy and safety of asundexian (BAY2433334) in the prevention of stroke in patients with atrial fibrillation and also patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA)
2
• OCEANIC-AF and OCEANIC-STROKE are expected to enroll more than 27,000 patients in over 40 countries Bayer’s competition in this arena is BMY/JNJ’s Milvexian (#msg-169818942, #msg-169841711), which is awaiting the start of phase-3.
👍️0
DewDiligence DewDiligence 2 years ago
BMY 4Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/02/02/bristol-myers-squibb-bmy-q4-2022-earnings-call-tra/
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s Sotyktu patients are coming approximately 1/3 from treatment-naïve, 1/3 for Otezla switches, and 1/3 from biologic switches. (Source: 4Q22 CC.)
👍️0
DewDiligence DewDiligence 2 years ago
BMY 4Q22 CC slides:

https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-Q4-2022-Results-Presentation-with-Appendix.pdf
👍️0
DewDiligence DewDiligence 2 years ago
BMY 4Q22 results—2023 guidance:

https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2022/default.aspx

2023 non-GAAP EPS guidance is $7.95-8.25; at the midpoint of the range, this is a 4% increase relative to 2022’s non-GAAP EPS of $7.70.
👍️0
DewDiligence DewDiligence 2 years ago
CHMP approves BMY’s Sotyktu for psoriasis:

https://www.businesswire.com/news/home/20230125005858/en
👍️0
DewDiligence DewDiligence 2 years ago
Addendum—Breyanzi is the first CAR-T to show efficacy in CLL, as far as I know. rrCLL is a large market; if Breyanzi’s complete-response rate after, say, 5 years is as high as 15-20%, this indication could be a meaningful commercial contributor.

Breyanzi, which is currently approved for various forms of relapsed NHL, has annualized sales of under $200M.
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s Breyanzi meets primary endpoint in rrCLL/SLL single-arm trial:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-transcend-115900140.html Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results from TRANSCEND CLL 004 showed the study met the primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor. The trial listing is at:
https://www.clinicaltrials.gov/ct2/show/NCT03331198
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s JPM webcast slides:

https://www.sec.gov/Archives/edgar/data/14272/000114036123000970/brhc10046308_99-1.htm
👍️0
DewDiligence DewDiligence 2 years ago
BMY’s Breyanzi continues to show robust results in second-line LBCL after longer follow-up:

https://www.fiercepharma.com/pharma/bristol-myers-bolsters-breyanzis-earlier-lymphoma-case-elevated-car-t-fight-against-gilead-0

Data from the same trial presented one year ago (at ASH 2021) are in #msg-164317285.
👍️0

Your Recent History

NYSE
BMY
Bristol Myers Squibb
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads